IFOSFAMIDE PLUS HIGH-DOSE CISPLATIN IN PATIENTS WITH NONSMALL CELL LUNG-CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY

This study determined the maximum tolerated dose (MTD) of ifosfamide t hat could be given with high-dose cisplatin to non-small cell lung can cer (NSCLC) patients previously treated with non-platin-containing che motherapy and to assess the efficacy of this combination. Twenty-three patients with inoperable NSCLC treated with one prior chemotherapy re gimen received continuous infusion ifosfamide 1.2 g/m(2) per day with MESNA for 5 days every 35 days and cisplatin 120 mg/m(2). After one pa tient who received cisplatin as a single dose developed grade 4 nephro toxicity and myelosuppression, cisplatin was given in four divided dos es (30 mg/m(2) per day) and the ifosfamide dose was lowered to 1.0 g/ m(2) per day, infused over 4 days. Dose-limiting grades 3 and 4 leukop enia was seen in 43%. A major objective response rate of 9% was observ ed, The 1-year survival was 30%, with a median survival of 6.4 months. The MTD of ifosfamide administered with cisplatin (30 mg/m(2) per day for 4 consecutive days) to this population of patients is 1.0 g/m(2) daily for 4 days, This combination produced limited anticancer activit y and significant toxicity. Excessive toxicity was observed when cispl atin was given as a single dose with ifosfamide, and this schedule sho uld not be used.